Nonalcoholic fatty liver disease: A review of current understanding and future impact

Michael Charlton

Research output: Contribution to journalArticle

281 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD), already the most common form of liver disease in the United States, can be expected to increase in prevalence and severity in parallel with national epidemics of obesity and type 2 diabetes. NAFLD is frequently associated with insulin resistance. While insulin resistance, and thereby hyperinsulinemia, are, in large part, metabolic consequences of obesity, the basis of diversity in severity and progression of inflammation and fibrosis is not known. Increased susceptibility to oxidative stress is likely to play a role. Several patient characteristics have been associated with more severe histological findings in patients with NAFLD, including type 2 diabetes, hypertension, age over 40 years, and higher transaminases. Liver biopsy is, however, required to accurately grade and stage NAFLD histologically. Although the natural history of NAFLD is relatively poorly defined, NAFLD is increasingly recognized as an important cause of decompensated liver disease. Weight reduction and improved insulin sensitivity are associated with improved biochemical and histological parameters of NAFLD. There are, however, no proven safe and efficacious pharmacological treatments for NAFLD.

Original languageEnglish (US)
Pages (from-to)1048-1058
Number of pages11
JournalClinical Gastroenterology and Hepatology
Volume2
Issue number12
DOIs
StatePublished - Dec 2004

Fingerprint

Insulin Resistance
Type 2 Diabetes Mellitus
Liver Diseases
Obesity
Non-alcoholic Fatty Liver Disease
Hyperinsulinism
Transaminases
Weight Loss
Oxidative Stress
Fibrosis
Pharmacology
Hypertension
Inflammation
Biopsy
Liver
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Nonalcoholic fatty liver disease : A review of current understanding and future impact. / Charlton, Michael.

In: Clinical Gastroenterology and Hepatology, Vol. 2, No. 12, 12.2004, p. 1048-1058.

Research output: Contribution to journalArticle

@article{28c6afa0b47e4c88b70edd584df7d16a,
title = "Nonalcoholic fatty liver disease: A review of current understanding and future impact",
abstract = "Nonalcoholic fatty liver disease (NAFLD), already the most common form of liver disease in the United States, can be expected to increase in prevalence and severity in parallel with national epidemics of obesity and type 2 diabetes. NAFLD is frequently associated with insulin resistance. While insulin resistance, and thereby hyperinsulinemia, are, in large part, metabolic consequences of obesity, the basis of diversity in severity and progression of inflammation and fibrosis is not known. Increased susceptibility to oxidative stress is likely to play a role. Several patient characteristics have been associated with more severe histological findings in patients with NAFLD, including type 2 diabetes, hypertension, age over 40 years, and higher transaminases. Liver biopsy is, however, required to accurately grade and stage NAFLD histologically. Although the natural history of NAFLD is relatively poorly defined, NAFLD is increasingly recognized as an important cause of decompensated liver disease. Weight reduction and improved insulin sensitivity are associated with improved biochemical and histological parameters of NAFLD. There are, however, no proven safe and efficacious pharmacological treatments for NAFLD.",
author = "Michael Charlton",
year = "2004",
month = "12",
doi = "10.1016/S1542-3565(04)00440-9",
language = "English (US)",
volume = "2",
pages = "1048--1058",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Nonalcoholic fatty liver disease

T2 - A review of current understanding and future impact

AU - Charlton, Michael

PY - 2004/12

Y1 - 2004/12

N2 - Nonalcoholic fatty liver disease (NAFLD), already the most common form of liver disease in the United States, can be expected to increase in prevalence and severity in parallel with national epidemics of obesity and type 2 diabetes. NAFLD is frequently associated with insulin resistance. While insulin resistance, and thereby hyperinsulinemia, are, in large part, metabolic consequences of obesity, the basis of diversity in severity and progression of inflammation and fibrosis is not known. Increased susceptibility to oxidative stress is likely to play a role. Several patient characteristics have been associated with more severe histological findings in patients with NAFLD, including type 2 diabetes, hypertension, age over 40 years, and higher transaminases. Liver biopsy is, however, required to accurately grade and stage NAFLD histologically. Although the natural history of NAFLD is relatively poorly defined, NAFLD is increasingly recognized as an important cause of decompensated liver disease. Weight reduction and improved insulin sensitivity are associated with improved biochemical and histological parameters of NAFLD. There are, however, no proven safe and efficacious pharmacological treatments for NAFLD.

AB - Nonalcoholic fatty liver disease (NAFLD), already the most common form of liver disease in the United States, can be expected to increase in prevalence and severity in parallel with national epidemics of obesity and type 2 diabetes. NAFLD is frequently associated with insulin resistance. While insulin resistance, and thereby hyperinsulinemia, are, in large part, metabolic consequences of obesity, the basis of diversity in severity and progression of inflammation and fibrosis is not known. Increased susceptibility to oxidative stress is likely to play a role. Several patient characteristics have been associated with more severe histological findings in patients with NAFLD, including type 2 diabetes, hypertension, age over 40 years, and higher transaminases. Liver biopsy is, however, required to accurately grade and stage NAFLD histologically. Although the natural history of NAFLD is relatively poorly defined, NAFLD is increasingly recognized as an important cause of decompensated liver disease. Weight reduction and improved insulin sensitivity are associated with improved biochemical and histological parameters of NAFLD. There are, however, no proven safe and efficacious pharmacological treatments for NAFLD.

UR - http://www.scopus.com/inward/record.url?scp=11144264156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144264156&partnerID=8YFLogxK

U2 - 10.1016/S1542-3565(04)00440-9

DO - 10.1016/S1542-3565(04)00440-9

M3 - Article

C2 - 15625647

AN - SCOPUS:11144264156

VL - 2

SP - 1048

EP - 1058

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 12

ER -